IL-36y is a strong inducer of IL-23 in psoriatic cells and activates angiogenesis
View/ Open
Graham_et_al_Frontiers_in_Immunology.pdf (2.117Mb)
Download
Publication date
2018-02-26Author
Bridgewood, CharlieFearnley, G.W.
Berekmeri, A.
Laws, P.
Macleod, T.
Ponnambalam, S.
Stacey, M.
Graham, Anne M
Wittman, Miriam
Rights
© 2018 Bridgewood, Fearnley, Berekmeri, Laws, Macleod, Ponnambalam, Stacey, Graham and Wittmann. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.Peer-Reviewed
YesOpen Access status
openAccess
Metadata
Show full item recordAbstract
The IL-1 family member cytokine IL-36γ is recognised as key mediator in the immunopathology of psoriasis, hallmarks of which involve the activation of both resident and infiltrating inflammatory myeloid cells and aberrant angiogenesis. This research demonstrates a role for IL-36γ in both myeloid activation and angiogenesis. We show that IL-36γ induces the production of psoriasis-associated cytokines from macrophages (IL-23 and TNFα) and that this response is enhanced in macrophages from psoriasis patients. This effect is specific for IL-36γ and could not be mimicked by other IL-1 family cytokines such as IL-1α. IL-36γ was also demonstrated to induce endothelial tube formation and branching, in a VEGF-A-dependent manner. Furthermore, IL-36γ-stimulated macrophages potently activated endothelial cells and led to increased adherence of monocytes, effects that were markedly more pronounced for psoriatic macrophages. Interestingly, regardless of stimulus, psoriasis monocytes showed increased adherence to both the stimulated and unstimulated endothelium when compared with monocytes from healthy individuals. Collectively, these findings show that IL-36γ has the potential to enhance endothelium directed leucocyte infiltration into the skin and strengthen the IL-23/IL-17 pathway adding to the growing evidence of pathogenetic roles for IL-36γ in psoriatic responses. Our findings also point to a cellular response, which could potentially explain cardiovascular comorbidities in psoriasis in the form of endothelial activation and increased monocyte adherence.Version
Published versionCitation
Bridgewood C, Fearnley GW, Berekmeri A et al (2018) IL-36y is a strong inducer of IL-23 in psoriatic cells and activates angiogenesis. Frontiers in Immunology. 9:200.Link to Version of Record
https://doi.org/10.3389/fimmu.2018.00200Type
Articleae974a485f413a2113503eed53cd6c53
https://doi.org/10.3389/fimmu.2018.00200